Evaluation of sitagliptin therapy on the levels of fibroblast growth factor-19 (FGF19) in patients with Type 2 diabetes

Authors : Özen ÖZ GÜL, Soner CANDER

Pages : 34-40

Doi:10.46310/tjim.1070223

View : 15 | Download : 12

Publication Date : 2022-04-01

Article Type : Research Paper

Abstract :Introduction: The specific association between sitagliptin and Fibroblast Growth Factor-19 insert ignore into journalissuearticles values(FGF19); is yet to be clarified. In this study, we aimed to investigate the effect of sitagliptin therapy on the levels of FDF19 in patients with type 2 diabetes mellitus insert ignore into journalissuearticles values(T2DM);. Methods: A total of 35 patients newly diagnosed type 2 diabetes, and who had not received antidiabetic treatment before were included in this study. Sitagliptin therapy was administered as 100 mg/day. Patients’ demographic, anthropometric features, glycaemic variables, lipid profiles and FGF19 values were evaluated at the baseline and at the 3rd month of the treatment and the obtained data were compared. Results: The mean age of the patients was 53.34 ± 8.09 years. The mean weight, body mass index insert ignore into journalissuearticles values(BMI);, hip circumference, postprandial blood glucose and glycosylated haemoglobin A1c insert ignore into journalissuearticles values(HbA1c); values were statistically significantly lower at the 3rd month of the treatment compared to the baseline values insert ignore into journalissuearticles values(for all, p<0.05);. The mean FGF19 was found as 84.37±64.23 pg/mL at the baseline and 86.06±44.10 pg/mL at the 3rd month of the treatment and the difference was not statistically significant insert ignore into journalissuearticles values(p=0.789);. A moderate negative correlation was found between FGF19, total cholesterol and low density lipoprotein cholesterol insert ignore into journalissuearticles values(LDL-c);, and a moderate positive correlation between FGF19 and triglycerides. Conclusion: This study did not show a significant effect of sitagliptin therapy on FGF19. T2DM variables such as postprandial blood glucose and HbAc1 were significantly improved. FGF19 was moderately correlated with total cholesterol and LDL-c in negative direction and with triglycerides in positive direction.
Keywords : Type 2 diabetes mellitus, fibroblast growth factor 19, sitagliptin, hyperglycemia, blood glucose